MoonLake Immunotherapeutics MLTX Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's shares (diluted)?
- MoonLake Immunotherapeutics (MLTX) reported shares (diluted) of 71.3M in Q1 2026.
- How has MoonLake Immunotherapeutics's shares (diluted) changed year-over-year?
- MoonLake Immunotherapeutics's shares (diluted) increased by 12.7% year-over-year, from 63.2M to 71.3M.
- What is the long-term trend for MoonLake Immunotherapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's shares (diluted) has grown at a 22.9% compound annual growth rate (CAGR), from 111.5M to 254.4M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.